The present invention is directed to novel imidazolidin-2-one derivatives having a structure according to Formula I ##STR00001## wherein a, b, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined above, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.